Intellia Therapeutics, Inc.

Intellia Therapeutics is a clinical-stage genome editing company focused on developing curative treatments using CRISPR/Cas9 technology. The company transforms medicine by permanently editing and correcting disease-associated genes within the human body through single-treatment therapies, addressing conditions that were previously untreatable. Intellia's pipeline includes in vivo programs targeting transthyretin amyloidosis and hereditary angioedema, along with proprietary programs developing engineered cell therapies for various cancers and autoimmune diseases. The company operates in the precision genomic medicine space, creating therapies aimed at genetic disorders and oncological conditions. Headquartered in Cambridge, Massachusetts and founded in 2014, Intellia represents a significant player in the evolving biopharmaceutical sector, contributing to next-generation therapeutics and personalized medicine approaches.